non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A research hub

Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)

This study looks at new drug combinations before surgery for early-stage lung cancer. We want to find the best ways to use these treatments to help patients prepare for surgery and to understand how they work with the body's immune system.